focus -WSS

focus

author：entertainment 2025-10-01 23:57:14 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Positive childhood experiences can help future health

focus

WSS

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Virtual Event: March of the Biosimilars

Nurses recount patients attacks

NIH trials fail to test meaningful long Covid therapies, experts say

Why failed clinical trials don’t always spell doom for a new drug

U.K. researchers warn about biases in medical devices, algorithms

entertainment

focus

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

UnitedHealth increases loan offers after Change Healthcare outage

Psychedelics group wrestles with new pharma identity

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Dobbs anniversary: the lost opportunity of abortion as health care

Drastic changes should bring profitability, startup health insurers say

Hollywood unions extend contract negotiations for actors

Creating egg and sperm cells from stem cells raises ethical issues

After affirmative action ruling, medical educators look to 'holistic review'

How to use technology to prevent future drug shortages

hotspot

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Readout Newsletter: Bluebird, CVS, Contineum

How to use technology to prevent future drug shortages

Neuroscience’s long legacy of racism

The best solution to the drug shortages problem

Methadone doses haven’t kept up in the age of fentanyl

focus

focus

hotspot

hotspot